Q4 2024 Management View CEO John Tucker highlighted FUROSCIX's Q4 2024 net revenue of $12.2 million, which aligns with the previously announced range of $12 million to $12.3 million. For the full year ...

Maxim analyst Naz Rahman lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $20 but keeps a Buy rating on the shares after ...

The Food and Drug Administration (FDA) has expanded the approval of Furoscix® (furosemide injection) to include the treatment of edema in patients with ...

Pharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S ...

Pharmaceuticals Inc (SCPH) reports a 167% revenue growth and strategic advancements, despite facing increased expenses and ...

scPharmaceuticals reported Q4 2024 revenue of $12.2 million, FDA approved FUROSCIX for chronic kidney disease, and a net loss of $18.8 million. FUROSCIX is indicated for treating edema in patients ...

We will then open the line for questions. Overall, although we're satisfied with the FUROSCIX commercial growth over the course of 2024, we were especially encouraged by what we saw in Q4 ...

Reports Q4 revenue $12.2M, consensus $12.18M..Reports Net FUROSCIX revenue of $12.2m and $36.3mfor the fourth quarter and full year 2024, ...

U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease ...

Management anticipates the Medicare redesign to positively impact FUROSCIX adoption. The redesign reduces patient out-of-pocket costs, which is expected to increase fill rates and demand.

scPharmaceuticals generated fourth quarter 2024 net FUROSCIX ® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31 ...